Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion type Assertion NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_head.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion description "[Our results suggest that PSK may augment anti-tumour action via genes including multidrug resistance protein 3 (MRP3), lymphotactin (Lptn), transgelin (TAGLN), and Pirin, without disturbing cell-cycle progression, and may deserve a large clinical trial in cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_provenance.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion evidence source_evidence_literature NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_provenance.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion SIO_000772 15547752 NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_provenance.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion wasDerivedFrom befree-20140225 NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_provenance.
- NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_assertion wasGeneratedBy ECO_0000203 NP236208.RAGId60SXfvLsrcsEEwCTAHIWDd3C6Xet07pNqUl_gsRQ130_provenance.